Why XenoPort Shares Stumbled – Motley Fool

by admin on May 20, 2013

Why XenoPort Shares Stumbled
Motley Fool
Sales projections for Horizant to treat restless leg syndrome are all over the place; but even at the low end of forecasts (around $90 million in peak sales), XenoPort is valued at about three times peak sales, giving shareholders some hope that if
XenoPort shares skid after MS drug proves to be a lemon in PhIIIFierceBiotech

all 13 news articles »

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: